All In Biotech

Drug Trial Radar · NCT00455507

A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa

Placebo-controlled, Double-blind, Parallel Group, Fixed Dose Study of KW-6002 (Istradefylline) in the Treatment of Parkinson's Disease (Phase 2 Study)

Last checked: Nov 20, 2026Latest source record: Aug 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 363 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

363

Actual

Start

Mar 2007

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's disease (PD) treated with levodopa.

Conditions

  • Parkinson's Disease

Interventions

  • IstradefyllineDrug

    Two 10 mg KW-6002 tablets orally once daily for 12 weeks

  • IstradefyllineDrug

    Two 20 mg tablets orally once a day for 12 weeks

  • PlaceboDrug

    Two placebo tablets orally once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with Parkinson's disease (PD) treated with levodopa/dopa-decarboxylase inhibitor.Time frame: Last Visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.